1. Detection of measurable residual disease may better predict outcomes than mutations based on next‐generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. (23rd February 2020) Authors: Wang, Jing; Lu, RunQing; Wu, Ying; Jia, JinSong; Gong, Lizhong; Liu, XiaoHong; Lu, ShengYe; Wang, Yu; Yan, ChenHua; Liu, KaiYan; Zhang, XiaoHui; Xu, LanPing; Jiang, Qian; Zhao, XiaoSu; Shi, HongXia; Lai, YueYun; Huang, XiaoJun; Ruan, GuoRui; Jiang, Hao Journal: British journal of haematology Issue: Volume 190:Number 4(2020) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study. (2022) Authors: Liu, Jing; Liu, Xiaohong; Jia, Jinsong; Gong, Lizhong; Lu, Shengye; Wang, Jing; Huang, Xiao-jun; Jiang, Hao Journal: Leukemia research reports Issue: Volume 18(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB–MYH11‐positive acute myeloid leukaemia indicates poor prognosis. (25th June 2020) Authors: Duan, Wenbing; Liu, Xiaohong; Jia, Jinsong; Wang, Jing; Gong, Lizhong; Jiang, Qian; Zhao, Ting; Wang, Yu; Zhang, Xiaohui; Xu, Lanping; Zhao, Xiaosu; Qin, Yazhen; Shi, Hongxia; Chang, Yingjun; Huang, Xiaojun; Jiang, Hao Journal: British journal of haematology Issue: Volume 192:Number 2(2021) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗